PloS one · 2026
Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kang Shuo, Yang Shuo, Jia Yize, Zhao Shan
Аннотация
BACKGROUND: The OptiTROP-Breast01 trial demonstrated the efficacy of sacituzumab tirumotecan for patients with metastatic triple-negative breast cancer (TNBC). The current analysis evaluated the cost-effectiveness of sacituzumab tirumotecan compared with chemotherapy for patients with metastatic TNBC from the Chinese health-care system perspective.
METHODS: A partitioned survival model (PSM) was developed to simulate 3-week patients in 10-year time horizon to access the disease course and cost-effectiveness of sacituzumab tirumotecan compared with chemotherapy for metastatic TNBC patients, cost and utility values were gathered from the dataset and published studies, annual discount rate of 5% was used. Total cost, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were the model outputs. Sensitivity analyses and subgroup analyses were conducted to estimate the robustness of the model outcomes.
RESULTS: In base-case analysis, compared with chemotherapy, sacituzumab tirumotecan could bring additional 0.41 LYs and 0.35 QALYs, with marginal costs of $55,927.31, resulting in the ICER of $162,799.04/QALY, which high than the willingness-to-pay (WTP) threshold of $40,326 per additional QALY gained. One-way sensitivity analyses revealed that the utility value was the main driver of the model outputs. Probabilistic sensitivity analyses showed the cost-effective probability of sacituzumab tirumotecan was 0% at the WTP threshold of $40,326/QALY. Subgroup analyses suggested that sacituzumab tirumotecan could not be considered cost-effective for all subgroup patients.
CONCLUSION: Sacituzumab tirumotecan was unlikely to be the cost-effective option for patients with metastatic TNBC compared with chemotherapy from the Chinese health-care system perspective, reduced the price of sacituzumab tirumotecan could increase its cost-effective.
METHODS: A partitioned survival model (PSM) was developed to simulate 3-week patients in 10-year time horizon to access the disease course and cost-effectiveness of sacituzumab tirumotecan compared with chemotherapy for metastatic TNBC patients, cost and utility values were gathered from the dataset and published studies, annual discount rate of 5% was used. Total cost, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were the model outputs. Sensitivity analyses and subgroup analyses were conducted to estimate the robustness of the model outcomes.
RESULTS: In base-case analysis, compared with chemotherapy, sacituzumab tirumotecan could bring additional 0.41 LYs and 0.35 QALYs, with marginal costs of $55,927.31, resulting in the ICER of $162,799.04/QALY, which high than the willingness-to-pay (WTP) threshold of $40,326 per additional QALY gained. One-way sensitivity analyses revealed that the utility value was the main driver of the model outputs. Probabilistic sensitivity analyses showed the cost-effective probability of sacituzumab tirumotecan was 0% at the WTP threshold of $40,326/QALY. Subgroup analyses suggested that sacituzumab tirumotecan could not be considered cost-effective for all subgroup patients.
CONCLUSION: Sacituzumab tirumotecan was unlikely to be the cost-effective option for patients with metastatic TNBC compared with chemotherapy from the Chinese health-care system perspective, reduced the price of sacituzumab tirumotecan could increase its cost-effective.